A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer

被引：0
|
作者：
Justin M Balko
Esther P Black
机构：
[1] College of Pharmacy,Department of Pharmaceutical Sciences
[2] University of Kentucky,undefined
来源：
BMC Cancer | / 9卷
关键词：
Progression Free Survival; Cetuximab; Erlotinib; KRAS Mutation; Lung Cancer Cell Line;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A gene expression predictor of response to EGFR-targeted therapy stratifies progression-free survival to cetuximab in KRAS wild-type metastatic colorectal cancer
    Balko, Justin M.
    Black, Esther P.
    BMC CANCER, 2009, 9
  • [2] Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
    Baker, J. B.
    Dutta, D.
    Watson, D.
    Maddala, T.
    Munneke, B. M.
    Shak, S.
    Rowinsky, E. K.
    Xu, L-A
    Harbison, C. T.
    Clark, E. A.
    Mauro, D. J.
    Khambata-Ford, S.
    BRITISH JOURNAL OF CANCER, 2011, 104 (03) : 488 - 495
  • [3] Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
    J B Baker
    D Dutta
    D Watson
    T Maddala
    B M Munneke
    S Shak
    E K Rowinsky
    L-A Xu
    C T Harbison
    E A Clark
    D J Mauro
    S Khambata-Ford
    British Journal of Cancer, 2011, 104 : 488 - 495
  • [4] EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
    Uhlyarik, Andrea
    Piurko, Violetta
    Papai, Zsuzsanna
    Raso, Erzsebet
    Lahm, Erika
    Kiss, Edina
    Sikter, Marta
    Vachaja, Jozsef
    Kenessey, Istvan
    Timar, Jozsef
    CANCERS, 2020, 12 (03)
  • [5] KRAS wild-type status predicts response to cetuximab in metastatic colorectal cancer
    Nature Clinical Practice Oncology, 2008, 5 (7): : 365 - 365
  • [6] KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy
    Valtorta, Emanuele
    Misale, Sandra
    Sartore-Bianchi, Andrea
    Nagtegaal, Iris D.
    Paraf, Francois
    Lauricella, Calogero
    Dimartino, Valentina
    Hobor, Sebastijan
    Jacobs, Bart
    Ercolani, Cristiana
    Lamba, Simona
    Scala, Elisa
    Veronese, Silvio
    Laurent-Puig, Pierre
    Siena, Salvatore
    Tejpar, Sabine
    Mottolese, Marcella
    Punt, Cornelis J. A.
    Gambacorta, Marcello
    Bardelli, Alberto
    Di Nicolantonio, Federica
    INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (05) : 1259 - 1265
  • [7] Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy
    Manceau, Gilles
    Imbeaud, Sandrine
    Thiebaut, Raphaele
    Liebaert, Francois
    Fontaine, Karine
    Rousseau, Francis
    Genin, Berengere
    Le Corre, Delphine
    Didelot, Audrey
    Vincent, Marc
    Bachet, Jean-Baptiste
    Chibaudel, Benoist
    Bouche, Olivier
    Landi, Bruno
    Bibeau, Frederic
    Leroy, Karen
    Penault-Llorca, Frederique
    Van Laethem, Jean-Luc
    Demetter, Pieter
    Tejpar, Sabine
    Rossi, Simona
    Mosakhani, Neda
    Osterlund, Pia
    Ristamaki, Raija
    Sarhadi, Virinder
    Knuutila, Sakari
    Boige, Valerie
    Andre, Thierry
    Laurent-Puig, Pierre
    CLINICAL CANCER RESEARCH, 2014, 20 (12) : 3338 - 3347
  • [8] EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab
    Razis, Evangelia
    Pentheroudakis, George
    Rigakos, George
    Bobos, Mattheos
    Kouvatseas, George
    Tzaida, Olympia
    Makatsoris, Thomas
    Papakostas, Pavlos
    Bai, Maria
    Goussia, Anna
    Samantas, Epaminontas
    Papamichael, Demetrios
    Romanidou, Ourania
    Efstratiou, Ioannis
    Tsolaki, Eleftheria
    Psyrri, Amanda
    De Roock, Wendy
    Bafaloukos, Dimitrios
    Klouvas, George
    Tejpar, Sabine
    Kalogeras, Konstantine T.
    Pectasides, Dimitrios
    Fountzilas, George
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (05) : 737 - 748
  • [9] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab
    De Roock, W.
    Piessevaux, H.
    De Schutter, J.
    Janssens, M.
    De Hertogh, G.
    Personeni, N.
    Biesmans, B.
    Van Laethem, J. -L.
    Peeters, M.
    Humblet, Y.
    Van Cutsem, E.
    Tejpar, S.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 508 - 515
  • [10] Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab
    Wadlow, Raymond
    Hezel, Aram F.
    Abrams, Thomas A.
    Blaszkowsky, Lawrence S.
    Fuchs, Charles S.
    Kulke, Matthew H.
    Kwak, Eunice L.
    Meyerhardt, Jeffrey A.
    Ryan, David P.
    Szymonifka, Jackie
    Wolpin, Brian M.
    Zhu, Andrew X.
    Clark, Jeffrey W.
    ONCOLOGIST, 2012, 17 (01): : E27 - E35
12345